Skip to content

Income Tax at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$561M+10.2%
Arcus Biosciences logo
Arcus BiosciencesRCUS
$0
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
$64K+23.1%
Biohaven logo
BiohavenBHVN
$272K-55.3%
Incyte logo
IncyteINCY
$40.27M-47.0%
Immunovant, Inc. logo
Immunovant, Inc.IMVT
$1.55M+921%

Other financials

Income statement

See full
Revenue$4.2M-95.0%
Operating income-$50.0M-214%
Net income-$44.5M-195%
EPS (diluted)-$0.45-179%

Balance sheet

See full
Cash & equivalents$159.9M+104%
Total debt$39.1M-6.7%
Total equity$521.9M+89.7%
Total assets$736.4M+87.3%

Cash flow

See full
Operating cash flow-$37.4M+17.9%
CapEx$1.9M+17.7%
Free cash flow-$39.2M+16.7%

Valuation

See full
Market cap$1.75B+361%
Enterprise value$1.63B+381%
P/S40.7×+38.4×

Profitability

See full
Operating margin-345.2%
Net margin-302.6%
FCF margin-45.8%-64.9pp

Returns & leverage

See full
Return on equity-32.6%
Debt / equity0.1×-0.1×
Current ratio9.5×+3.9×

Where this comes from

Reported directly by Monte Rosa Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncomeTaxExpenseBenefit.

The official record: Monte Rosa Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Monte Rosa Therapeutics, Inc.'s income tax.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Monte Rosa Therapeutics, Inc.'s income tax?
Monte Rosa Therapeutics, Inc. (GLUE) reported income tax of $52K in Q1 2026.
How has Monte Rosa Therapeutics, Inc.'s income tax changed year-over-year?
Monte Rosa Therapeutics, Inc.'s income tax decreased by 93.7% year-over-year, from $822K to $52K.
What does income tax mean?
Total income tax expense (current + deferred) recognized in the income statement, representing the company's total tax obligation on pre-tax income.